Bavarian Nordic A/S BAVA

The Danish biotech sharpened its global vaccine ambitions by tapping Tarja Stenvall, a Big Pharma vet, to take the helm.

COPENHAGEN, Denmark, September 28, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on September 1, 2026, under which the Company will repurchase shares for an amount up to DKK 250 million in the period from September 1, 2026 to October 30, 2026. The program is executed in accordance with Regulation (EU) No. 596/2014 (as amended) of the European Parliament and of the Council on market abuse and Commission Delegated Regulation (EU) 2016/1052,

COPENHAGEN, Denmark, September 22, 2026 - Pursuant to Section 31 of the Danish Capital Markets Act, it is hereby announced that as of September 21, 2026, Bavarian Nordic’s holding of treasury shares amounted to 3,965,413 shares, corresponding to 5.00% of the Company’s share capital and voting rights in the Company. In accordance with Section 85 of the Danish Companies Act, the Company cannot exercise any voting rights attached to its treasury shares. The increased holding of treasury shares to m

COPENHAGEN, Denmark, September 17, 2026 – Bavarian Nordic A/S (OMX: BAVA) today announced that Tarja Stenvall has been appointed President and Chief Executive Officer, effective October 15, 2026, succeeding Paul Chaplin whose departure was announced earlier this year. Tarja Stenvall is a global healthcare executive with over 20 years of leadership experience from Sanofi, AstraZeneca, and Pfizer, combining deep commercial expertise with a proven track record of building and transforming businesse

COPENHAGEN, Denmark, September 4, 2026 – Bavarian Nordic A/S (OMX: BAVA) has received information about the following transactions of the company’s shares/related securities by persons holding managerial responsibilities and/or persons/companies closely associated with such. 1.Details of the person discharging managerial responsibilities/person closely associated a)NameRussell Thirsk2.Reason for the notificationa)Position/statusExecutive Vice President and Chief Operating Officer of Bavarian Nor

COPENHAGEN, Denmark, September 4, 2026 – Bavarian Nordic A/S (OMX: BAVA) announced today that the Company's share capital has been increased by nominally DKK 285,900 as a consequence of employees’ exercise of warrants. The capital increase was effected without any pre-emption rights for the existing shareholders of the Company or others. A total of 28,590 new shares were subscribed for in cash at DKK 190.11 per share of nominally DKK 10. The total proceeds to Bavarian Nordic A/S from the capital

COPENHAGEN, Denmark, September 1, 2026 – Bavarian Nordic A/S (OMX: BAVA) today launches the first tranche of the new share buy-back program announced on August 21, under which the Company intends to repurchase own shares for up to DKK 750 million. The first tranche will comprise buy-back of shares for up to DKK 250 million. The purpose of the new share buy-back program is to adjust the capital structure, through subsequent cancellation of shares repurchased under this program, subject to any nec

Bavarian Nordic stock has delivered a solid 36.1% return over the past three years, while a fresh intrinsic value estimate using a Discounted Cash Flow (DCF) approach indicates the shares trade at a sizeable discount to that model. At the same time, market based multiples look roughly in line with peers, which leaves investors weighing a high value score against a more neutral read from traditional ratios. Over the past three years the share price is up 36.1%, which signals that investors...

Bavarian Nordic AS (BVNKF) raises FY2026 revenue and EBITDA guidance on robust Travel Health and Public Preparedness performance, while navigating Chikungunya headwinds and advancing its pipeline.

COPENHAGEN, Denmark, August 21, 2026 – Bavarian Nordic A/S (OMX: BAVA) announced today its interim financial results and business progress for the second quarter and first half of 2026 and released its financial calendar for 2027. Financial highlights Revenue in the second quarter (Q2) increased by 23% to DKK 2,034 million. Travel Health revenue increased by 45% (56% when adjusting for discontinued partnerships) to DKK 1,022 million, primarily driven by continued strong RabAvert/Rabipur sales (D

Guidance upgrade reflects upper end of previous guided revenue range and an improved EBITDA margin COPENHAGEN, Denmark, August 21, 2026 – Bavarian Nordic A/S (OMX: BAVA) today announced an upgrade of the Company’s financial guidance for the full year 2026, reflecting continued strength in the Public Preparedness business. Total revenue is now expected at approximately DKK 5,700 million, corresponding to the upper end of the previous guidance range (DKK 5,500 – 5,700 million). The upgraded guidan

MVA-BN approval expanded to include children aged 2 to less than 12 years for protection against mpox, smallpox and disease caused by vaccinia virusApproval further strengthens MVA-BN’s position in supporting global public health preparedness COPENHAGEN, Denmark, August 7, 2026 – Bavarian Nordic A/S (OMX: BAVA) announced today that the European Commission has adopted the recent Committee for Medicinal Products for Human Use (CHMP) positive opinion recommending the approval of a type II variation

COPENHAGEN, Denmark, July 13, 2026 – Bavarian Nordic A/S (OMX: BAVA) today announced that its partner, Eurofarma, has submitted a marketing authorization application to the Brazilian Health Regulatory Agency (Anvisa) for Bavarian Nordic’s chikungunya vaccine, CHIKV VLP, for the prevention of disease caused by chikungunya virus in individuals 12 years of age and older. The submission represents a key milestone in the partnership established between Bavarian Nordic and Eurofarma and marks an impor

COPENHAGEN, Denmark, July 13, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces that the share buy-back program, which was announced and initiated on June 2, 2026, has now been completed, reaching an aggregate amount of approximately DKK 150 million as planned. This represented the third and final tranche of a total planned share buy-back of up to DKK 500 million in 2026. Bavarian Nordic will hold the shares bought back as treasury stock, for the purpose of adjusting the capital structure. The pr